Alan H. Auerbach has served as our Chairman of the Board and as our Chief Executive Officer and President since our inception. Prior to founding Puma, Mr. Auerbach served as Founder, Chief Executive Officer, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from the company's inception in 2003 until its acquisition by Johnson & Johnson in July 2009.
From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the European Union in September 2011.
Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by the company. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology.
Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California.
What is Alan H. Auerbach's net worth?
The estimated net worth of Alan H. Auerbach is at least $20.06 million as of July 17th, 2024. Mr. Auerbach owns 7,063,515 shares of Puma Biotechnology stock worth more than $20,060,383 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Auerbach may own. Additionally, Mr. Auerbach receives an annual salary of $1,300,000.00 as CEO at Puma Biotechnology. Learn More about Alan H. Auerbach's net worth.
How old is Alan H. Auerbach?
What is Alan H. Auerbach's salary?
How do I contact Alan H. Auerbach?
Has Alan H. Auerbach been buying or selling shares of Puma Biotechnology?
Alan H. Auerbach has not been actively trading shares of Puma Biotechnology over the course of the past ninety days. Most recently, Alan H. Auerbach sold 21,920 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $3.70, for a transaction totalling $81,104.00. Following the completion of the sale, the chief executive officer now directly owns 7,063,515 shares of the company's stock, valued at $26,135,005.50. Learn More on Alan H. Auerbach's trading history.
Who are Puma Biotechnology's active insiders?
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 174,074 shares worth more than $667,379.98. The most recent insider tranaction occured on August, 12th when Director Michael Patrick Miller sold 23,358 shares worth more than $81,519.42. Insiders at Puma Biotechnology own 23.7% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 8/12/2024.
